Skip to content
drillr.ai

OGN

Organon & Co.

NYSE · USHealthcareDrug Manufacturers - General
$13.49-0.22%

Price as of Jul 20, 2026

OGN news

Organon & Co. news

A server-rendered, paginated timeline of the latest available company news.

  1. Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders?

    Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for o

    PR Newswire ·

  2. Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

    Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com%2F&esheet=54559853&newsitemid=20260624575652&lan=en-US&anchor=Kahn+Swick+%26amp%3B+Foti&index=1&md5=3ef5989c659dcf9d0631a17fc60bb7b6) , LLC (“KSF”) are investigating the propos

    Business Wire ·

  3. Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

    Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS(®) (denosumab injection) and TUZEMTY(® )(denosumab injection), Biosimilars to PROLIA and XGEVA The launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas Organon Canada and Shanghai Henlius Biotech, Inc. (2696.HK) today announced that BILDYOS(®) (denosumab injection) 60 mg/1 mL and TUZEMTY(®) (denosumab injection) 120 mg/1.7 mL, biosimilars to PROLIA and X

    Business Wire ·

  4. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

    BALA CYNWYD, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Apogee Therapeutics, Inc. (Nasdaq – APGE) Under the terms of the Merger Agreement, Apogee will be acquired by AbbVie (NYSE – ABBV) for $135.11 per share in cash

    Globe Newswire ·

  5. Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

    Organon Completes Agreement to License MIUDELLA(®), Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device This transaction strengthens Organon’s contraception portfolio and expands long-acting reversible options for women Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA

    Business Wire ·

  6. Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

    Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA(®) (ustekinumab), a Biosimilar Referencing STELARA(®) (ustekinumab) in Canada The amended agreement deepens Organon and Samsung Bioepis’s collaboration to six biosimilars in Canada across multiple therapeutic areas, including immunology, oncology and dermatology. To be launched in Canada in 2026 Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their d

    Business Wire ·

  7. Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  8. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)

    BALA CYNWYD, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Simulations Plus, Inc. (Nasdaq – SLP) Under the terms of the Merger Agreement, Simulations Plus will be acquired by Altaris, LLC (“Altaris”) for $18.50 per shar

    Globe Newswire ·

  9. Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

    Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE(®) (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE(® )(tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adu

    Business Wire ·

  10. Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  11. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), SUNation Energy, Inc. (Nasdaq – SUNE), Organon & Co. (NYSE – OGN), Taylor Morrison Home Corporation (NYSE – TMHC)

    BALA CYNWYD, Pa., June 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Nuvalent, Inc. (Nasdaq – NUVL) Under the terms of the Merger Agreement, Nuvalent will be acquired by GSK plc (NYSE – GSK) for $124.00 per share in cash in a dea

    Globe Newswire ·

  12. SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)

    Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 2, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Organon & Co. ("Organon" or the "Company") (NYSE - OGN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Sun Pharmaceutical Industries Limited for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75 billion.

    Newsfile Corp ·

  13. Organon to Present New Research on Access and Value at ISPOR 2026

    Organon to Present New Research on Access and Value at ISPOR 2026 New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific confer

    Business Wire ·

  14. Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

    Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for ou

    PR Newswire ·

  15. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)

    BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Veris Residential, Inc. (NYSE – VRE) Under the terms of the Merger Agreement, Veris will be acquired by Affinius Capital in partnership with Vista Hill Partners

    Globe Newswire ·

  16. Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  17. SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX

    SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX PR Newswire NEW YORK, May 6, 2026 NEW YORK, May 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682320-2&h=2140669980&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde)  with Monteverde & Associates PC (https://edge.prnewswire.com

    PR Newswire ·

  18. Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  19. Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  20. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

    BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. XOMA Royalty Corporation (Nasdaq – XOMA) Under the terms of the Merger Agreement, XOMA will be acquired by Ligand Pharmaceuticals Incorporated (Nasdaq - LGND) fo

    Globe Newswire ·